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Abstract
Huntington’s disease (HD) is a progressive neurodegenerative disorder for which there is no effective disease modifying
treatment. Following-on from studies in HD animal models, histone deacetylase (HDAC) inhibition has emerged as an
attractive therapeutic option. In parallel, several reports have demonstrated a role for histone deacetylase 6 (HDAC6) in the
modulation of the toxicity caused by the accumulation of misfolded proteins, including that of expanded polyglutamine in
an N-terminal huntingtin fragment. An important role for HDAC6 in kinesin-1 dependent transport of brain-derived
neurotrophic factor (BDNF) from the cortex to the striatum has also been demonstrated. To elucidate the role that HDAC6
plays in HD progression, we evaluated the effects of the genetic depletion of HDAC6 in the R6/2 mouse model of HD. Loss
of HDAC6 resulted in a marked increase in tubulin acetylation throughout the brain. Despite this, there was no effect on the
onset and progression of a wide range of behavioural, physiological, molecular and pathological HD-related phenotypes.
We observed no change in the aggregate load or in the levels of soluble mutant exon 1 transprotein. HDAC6 genetic
depletion did not affect the efficiency of BDNF transport from the cortex to the striatum. Therefore, we conclude that
HDAC6 inhibition does not modify disease progression in R6/2 mice and HDAC6 should not be prioritized as a therapeutic
target for HD.
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Introduction
Huntington’s disease (HD) is an autosomal dominant progres-
sive neurodegenerative disorder with a mean age of onset of 40
years [1]. The most characteristic features of symptomatic HD
patients are motor disorders, cognitive decline, psychiatric
disturbances and weight loss. The disease progresses on average
for 15–20 years and although the first symptomatic drug has
recently been approved by the Federal Drug Administration, there
is still no disease modifying treatment available [2]. The cause of
HD is the expansion of a CAG trinucleotide repeat in the HTT
gene, resulting in an expanded polyglutamine (polyQ) tract in the
N-terminus of the huntingtin protein [3]. HD pathology is mostly
observed in the brain with the striatum displaying pronounced
atrophy, although other brain regions are also affected [4,5]. A
prominent feature of HD is the presence of mutant huntingtin
containing cytoplasmic aggregates and nuclear inclusions that are
ubiquitin positive [6]. At the molecular level, many changes have
been observed that may contribute to HD pathology including
abnormal levels of neurotransmitters and their receptors, mito-
chondrial dysfunction, metabolic disturbances, transcriptional
dysregulation and disruption of microtubule based transport,
among others [7].
Histone deacetylases (HDACs) have been proposed as possible
therapeutic targets for HD [8]. There are altogether 18
mammalian HDAC’s, divided into four classes depending on
their homology to yeast enzymes. Class I and II enzymes have
Zn
2+ dependent catalytic domains and are homologous to yeast
Rpd3 and Hda1, respectively. HDAC11 is also Zn
2+ dependent
but has been placed in a separate category (class IV) due to a lack
of sufficient sequence similarity to any other group [9]. Sirtuins
(class III) are homologous to yeast Sir2 and use a different
mechanism requiring NAD
+ as a co-factor [10]. Studies on HDAC
inhibition have shown promising results in fly, worm and mouse
models of HD [11,12,13,14].
HDAC6 is a target of some of the broad range HDAC inhibitors
includingsuberoyl anilidehydroxamicacid (SAHA) andtrichostatin
A (TSA) [15]. It is a particularly interesting protein, in that it is the
only known HDAC with two catalytically active deacetylase
domains and a ubiquitin interacting domain [16,17]. Moreover,
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shown todeacetylatea-tubulin, HSP90andcortactin,amongothers
[18,19,20,21]. HDAC6 is also of particular interest in HD. In cell
models, HDAC6 has been shown to act against protein misfolding
toxicity by taking part in the formation of a juxtanuclear structure
termed the aggresome, a microtubule dependent inclusion body to
which dispersed aggregates are targeted and transported by the
dynein motor [22]. HDAC6 is required for the targeting of
ubiquitinated aggregates to the aggresome, thought to serve as an
adaptor protein by binding both poly-ubiquitin chains and the
dynein motor. Interestingly, deacetylase activity and intact
microtubules are essential to this process implying that aggresome
formation depends on tubulin acetylation status [23]. Similarly, it
has been shown that HDAC6 is critical for the formation of stress
granules [24]. In addition, it has recently been shown that in the
case of proteasome overload, aggresome formation might provide
the means by which the cell removes accumulated misfolded
proteins byautophagyandthat HDAC6is essentialforthis pathway
[25]. In a Drosophila melanogaster model of spinal and bulbar muscular
atrophy (SBMA) HDAC6 expression rescued neurodegeneration in
an autophagy-dependent manner [26]. In fact, HDAC6 has also
recently been shown to be involved in ubiquitin selective quality
control autophagy by regulating the lysosome to autophagosome
fusion [27]. On the other hand, a study in an HD cell model has
indicated that increasing tubulin acetylation by HDAC6 inhibition
could rescue the brain-derived neurotrophic factor (BDNF)
transport deficit from the cortex to the striatum [28]. Taken
together, these findings strongly suggest that HDAC6 inhibition
should modify HD progression.
Based on the previous studies in cell culture models of HD, we
might expect that loss of HDAC6 would increase aggregate load and
exacerbate the phenotype in a mouse model of HD. On the other
hand, an increase in cortico-striatal BDNF transport might be
expected to improve some HD-related phenotypes. To determine
whether HDAC6 regulates aggregate formation and turnover and/or
plays a role in BDNF transport in a mouse model of HD, we crossed
the R6/2 transgene onto an Hdac6 knock-out background. As Hdac6
is located on the X-chromosome, hemizygous male mice are
nullizygous for Hdac6 [29]. The R6/2 mouse has an early onset
and rapid phenotype progression [30] and at late stage disease
expresses HD-related phenotypes that are extremely similar to those
that develop in the HdhQ150 knock-in model of HD
[31,32,33,34,35]. We showed that in the absence of HDAC6, levels
of tubulin acetylation were increased throughout the brain. However,
this had no effect on R6/2 readouts in a battery of physiological and
behavioural assessments. We also found no difference in levels of
soluble or aggregated huntingtin trans-protein upon ablation of
H D A C 6 .O u rd a t at h u ss u g g e s tt h a tH D A C 6i sn o ti m p o r t a n tf o r
aggregate clearance in a mouse model of HD. Finally, we established
that increased tubulin acetylation did not affect levels of BDNF in the
striatum. We conclude that inhibition of HDAC6 should not be
pursued as a high priority therapeutic target for HD.
Results
Hdac6knock-out mice (Hdac6KO)areviableandfertile,and donot
show any overt phenotypes [36]. Before analysing the effect of the
genetic depletion of HDAC6 on phenotype progression in the R6/2
mice, we wanted to verify that these mice do not express HDAC6 at
the mRNA or protein level. cDNA was prepared from cortex,
striatum, cerebellum, muscle and liver from 4 week old wild type
(WT)andHdac6KO mice and analysed by real-time quantitative RT-
PCR (qPCR). Hdac6 was not expressed in tissue from Hdac6KO mice
(Fig. 1A). HDAC6 protein could not be detected in brain or testes by
western blot analysis (Fig. 1B). Consistent with previous reports,
HDAC6 levels were higher in testes than in brain [36]. R6/2 mice in
our colony reach end-stage disease at 15 weeks of age. In order to
determine whether Hdac6 is stably expressed during this disease time-
frame, we compared the levels of Hdac6 mRNA in WT mice at 4, 9
and 15 weeks of age. We established that Hdac6 is expressed at
relatively stable levels in WT mice from 4 to 15 weeks of age, with
only a 15% reduction being detected in the cortex at 9 weeks as
compared to 4 weeks of age (Fig. 1C). Transcriptional dysregulation is
a hallmark of the molecular pathogenesis of HD and is recapitulated
by the R6/2 mouse model [37]. Thus, to ensure that Hdac6 is not
dysregulated in R6/2 mice, we measured Hdac6 expression levels in
R6/2 mice at 4, 9 and 15 weeks of age in cortex, striatum and
cerebellum and compared them to those observed in WT mice.
Hdac6 levels were unchanged between WT and R6/2 mice (Fig. 1D)
indicating that there was no effect of disease progression on the
expression of Hdac6.
Tubulin is hyperacetylated upon genetic depletion of
HDAC6 but is not altered by the presence of the R6/2
transgene
As HDAC6 is an a-tubulin deacetylase, depletion of HDAC6
should result in tubulin hyper-acetylation. It has been previously
reported that the Hdac6KO line of mice used in this study, has
elevated levels of acetylated tubulin in peripheral tissue but not in
brain [36]. However, increased tubulin acetylation has been
shown to occur in brain as a consequence of HDAC6 depletion in
an alternative Hdac6 knock-out mouse [38]. To resolve this
discrepancy, we analysed tubulin acetylation in our Hdac6KO
mice by western blotting, normalising levels of acetylated tubulin
to those of total a–tubulin. We found that tubulin is hyperace-
tylated in the cortex, striatum and cerebellum of Hdac6KO mice at
4, 9 and 15 weeks of age as compared to WT littermates (Fig. 2A
and C). The extent of hyperacetylation in Hdac6KO mice became
less pronounced with age in the cortex and cerebellum, perhaps
explaining the earlier results.
Acetylation of lysine 40 on a-tubulin has been demonstrated to
increase the binding of certain molecular motor proteins to
microtubules, thus modulating intracellular transport dynamics
[39]. Impairment of intracellular transport has been suggested to
contribute to the molecular pathology of HD [40]. Therefore, we
investigated whether tubulin acetylation is altered by the presence
of the R6/2 transgene. Our results indicate that there is no
difference in tubulin acetylation between R6/2 and WT mice in
cortex, striatum and cerebellum at 4, 9 or 15 weeks of age (Fig. 2B
and D). This is consistent with the fact that there is no difference in
the expression of Hdac6 between WT and R6/2 mice in the same
tissues throughout disease progression (Fig. 1D).
Genetic Depletion of HDAC6 does not modify HD
physiological and behavioural phenotypes in R6/2 mice
Previous studies have indicated that both over-expression and
depletion of HDAC6 could ameliorate HD phenotypes in cell
culture [25,28]. Here, we investigate whether HD-related
phenotypes are modulated by the genetic depletion of HDAC6
in an HD mouse model. R6/2 males were bred to Hdac6KO
heterozygous females and a longitudinal phenotyping study was
performed to compare Hdac6KOxR6/2 double mutant (Dble)
mice to WT, Hdac6KO and R6/2 littermates. As Hdac6 is an X-
linked gene [29], males carrying the mutant allele are effectively
nullizygous for Hdac6 (Fig. 1A–B). We obtained at least 16 males
for each genotype and the R6/2 and Dble groups were well
matched for their CAG repeat size (p=0.338) (Fig. 3A).
No Effect of Hdac6 Knock-Out in an HD Mouse Model
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age onwards (Fig. 3B). R6/2 mice weighed significantly less than
WT mice overall (F(1,64)=14.28, p,0.001) and gained weight at a
significantly slower rate (F(2,640)=55.99, p,0.001). HDAC6
depletion by itself had no impact on the weight (F(1,64)=0.567,
p=0.454) and weight gain (F(2,640)=0.247, p=0.741) when
compared to WT mice. Absence of HDAC6 did not affect the
loss of weight in R6/2 (F(1,64)=0.007, p=0.931) or the decreased
rate in weight gain (F(2,640)=0.512, p=0.567). These data indicate
that depletion of HDAC6 does not affect weight loss in the R6/2
mice (Fig. 3B).
RotaRod measures motor coordination and balance, both of
which become significantly impaired in R6/2 mice. Here the
animals were subjected to RotaRod analysis at 4, 8, 10, 12 and 14
weeks of age (Fig. 3C). As expected, R6/2 mice performed worse
than WT mice (F(1,71)=39.74, p,0.001) and that performance
deteriorated over the course of the study (F(3,1420)=18.23,
p,0.001). The performance of Hdac6KO mice was similar to
WT (F(1,71)=0.32, p=0.573) but the variability in their perfor-
mance over time was significantly different to that of WT mice
(F(3,1420)=3.53, p=0.020). Nevertheless, the Hdac6 knock-out
genotype did not modify the performance of R6/2 mice overall
(F(1,71)=0.40, p=0.529) or with age (F(3,1420)=1.09, p=0.352).
Forelimb grip strength was measured at 4 weeks of age and
weekly from 11 to 14 weeks of age (Fig. 3D). As expected, the
overall grip strength of R6/2 mice was worse than that of WT
(F(1,67)=142.41, p,0.001) and deteriorated over time
(F(3,536)=50.69, p,0.001). The grip strength of Hdac6KO mice
was no different from WT mice either overall (F(1,67)=0.621,
p=0.434) or with time (F(3,536)=1.97, p=0.121). Nullizygosity for
Hdac6 did not have an effect on the overall grip strength of R6/2
mice (F(1,67)=3.17, p=0.081) nor did it influence the deterioration
in grip strength over the course of the experiment (F(3,536)=0.856,
p=0.463). Therefore, genetic depletion of HDAC6 does not
modify loss of forelimb muscle strength in R6/2 mice.
Spontaneous motor activity was recorded for each mouse for
30 min in an infrared activity monitoring cage bi-weekly from 5
weeks of age onwards (Fig. 3E and Fig. S1). Data were analysed by
repeated measures general linear model ANOVA and p-values are
presented in Table S1. At 5 weeks of age, levels of activity between
mice of all genotypes were comparable (Fig. 3E and Table S1: R6/
2 Genotype and Hdac6KO Genotype), but a significant difference
in the pattern of activity over time was already evident for activity
(p=0.011) and rearing (p=0.016) for mice carrying the R6/2
transgene. At 7 weeks of age the R6/2 genotype significantly
affected the activity and mobility (p,0.001) of the mice. A clear
Figure 1. HDAC6 expression in Hdac6KO, WT and R6/2 mice. (A) Taqman qPCR assay showing absence of Hdac6 mRNA expression in Hdac6KO
mice as compared to WT; n=3/genotype. Data normalised to Atp5b and expressed as fold change of WT for each tissue. (B) Western blot showing
absence of HDAC6 protein expression in Hdac6KO mice as compared to WT. (C) Taqman qPCR assay showing that Hdac6 mRNA expression does not
change with age in WT mice in cortex, striatum and cerebellum; n=8/genotype, data normalised to Atp5b and Rpl13a (cortex), Gapdh (striatum) and
18S RNA (cerebellum) and expressed as fold change of 4 weeks. (D) Taqman qPCR assay showing no difference in Hdac6 mRNA expression between
WT and R6/2 mice in cortex, striatum and cerebellum at 4, 9 and 15 weeks; n$6/genotype, data normalised to WT for each time point and brain
region. Error bars represent SEM. * p,0.05 as compared to 4 weeks. KO – Hdac6 knock out, WT – wild type, Cor - cortex, Str - striatum, Cer -
cerebellum, Mus - muscle, Liv - liver.
doi:10.1371/journal.pone.0020696.g001
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and 13 weeks of age (Fig. 3E and Table S1, R6/2 Genotype).
Hdac6KO mice were comparable to WT and the Dble mutant
mice to R6/2 at almost all time points indicating that depletion of
HDAC6 had no influence on the R6/2 hypoactivity phenotype.
Mice were sacrificed at 15 weeks of age and brains weighed to
the nearest 0.001 g (Fig. 3F). As expected, R6/2 mice had a
significantly lower brain weight than WT mice (p,0.001). The
weight of Hdac6KO brains was similar to WT (p,0.057) and that
of the Dble mutant mice was similar to R6/2 (p=0.784). Thus,
absence of HDAC6 does not modify the loss in brain weight
exhibited by the R6/2 mice at end-stage disease.
Genetic Depletion of HDAC6 does not modify huntingtin
aggregation
Aggregation of mutant huntingtin is a prominent feature of HD
neuropathology and occurs in all of the HD rodent models that have
thus far been developed. Aggregates in the R6/2 mouse appear prior
to the onset of behavioural symptoms and continue to accumulate
throughout the course of the disease. At the same time, a steady
decrease in the levels of soluble transprotein can be observed. In cells,
HDAC6 acts as a linker between ubiquitinated protein and/or
aggregates and the dynein/dynactin motor complex enabling their
transport to the aggresome for autophagic degradation [23]. If this
phenomenon is relevant to the mammalian brain, an absence of
HDAC6 should result in an increase in aggregate load [25].
We measured the amount of SDS insoluble aggregates by the
Seprion ligand ELISA [34] and found no difference in aggregate
load between R6/2 and Dble mice at 4, 9 and 15 weeks of age in
cortex, hippocampus and brain stem (Fig. 4A and Fig. S2A), or at
9 and 15 weeks in quadriceps muscle (Fig. S2E). The
corresponding levels of soluble transprotein were measured in
these tissues by means of TR-FRET (Fig. 4B and Fig. S2D–E),
similarly, no difference between R6/2 and Dble mice was
detected. These results were confirmed by a TR-FRET aggrega-
tion assay (Fig. S2D) and by western blotting of SDS-PAGE
resolved lysates with an antibody that detects soluble and
aggregated huntingtin (S830) (Fig. 4C and Fig. S2B).
Our data show that HDAC6 ablation does not influence
aggregate load or levels of soluble mutant huntingtin in the cortex,
hippocampus or brain stem at 4, 9 or 15 weeks of age (Fig. 4, Fig.
S2A–C) or in quadriceps muscle at 9 and 15 weeks of age (Fig.
S2E). In support of this, we did not detect any obvious differences
in the level or distribution of aggregates between R6/2 and Dble
Figure 2. Tubulin acetylation in the brains of Hdac6KO and R6/2 mice compared to WT. (A–B) Representative western blots showing
acetylated tubulin (Ac-tub) between Hdac6KO and WT mice (A) and R6/2 and WT mice (B) at 4, 9 and 15 weeks in cortex, striatum and cerebellum
with tubulin (Tub) as a loading control. (C–D) Densitometric quantification of western blots represented in (A–B). Acetylated tubulin was normalised
to a-tubulin and the relative signal for Hdac6KO (C) or R6/2 (D) expressed as fold change compared to WT. Error bars represent SEM. * p,0.05,
** p,0.01, *** p,0.001; n$4/genotype. KO – Hdac6 knock out, WT – wild type.
doi:10.1371/journal.pone.0020696.g002
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Although a significant decrease in soluble cortical transprotein
levels was detected by TR-FRET in the Dble as compared to the
R6/2 mice at 9 weeks of age, further analysis by western blot has
shown that this difference, if real, is not large (Fig. 4B–C). At the
same age, there was no difference in the cortical aggregate load
measured by either Seprion ELISA or TR-FRET (Fig. 4A and Fig.
S2D).
Genetic Depletion of HDAC6 results in tubulin
hyperacetylation in the brains of R6/2 mice
We have found that the absence of HDAC6 has no effect on
R6/2 behavioural phenotypes or on the accumulation of
aggregated transprotein in these animals. It is possible that the
presence of the R6/2 transgene prevented the hyperacetylation of
tubulin from occurring in response to HDAC6 depletion.
Therefore, we compared the levels of acetylated tubulin between
R6/2 and Dble mice at 4, 9 and 15 weeks of age in the cortex,
striatum and cerebellum. We found that HDAC6 depletion
resulted in a pronounced increase in tubulin acetylation in R6/2
mice in all brain regions and at all time-points studied (Fig. 5).
The increase in tubulin acetylation was comparable between
Hdac6KO and Dble mutant mice (Fig. S3). We conclude that the
substantial increase in tubulin acetylation levels throughout the
brain has no consequence on HD-related phenotypes in the R6/2
mouse.
Figure 3. Behavioural and physiological phenotypes in the absence of HDAC6. (A) The number of male mice analysed per genotype with
the mean CAG repeat size for the groups carrying the R6/2 transgene (SD-standard deviation). (B) Body weight (C) Time spent on RotaRod (D)
Forelimb grip strength (E) Spontaneous motor activity recorded at the beginning (week 5) and end (week 13) of the study. Graphs were created by
plotting 5 min moving averages (F) Brain weight measured at week 15. Error bars represent SEM.
doi:10.1371/journal.pone.0020696.g003
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content in the striatum
Cell culture studies have shown that an increase in tubulin
acetylation increases the transport of BDNF from the cortex to
the striatum in the context of both WT and HD [28]. In
accordance with previous data [41], we found that Bdnf mRNA
expression is lower in the cortex of R6/2 mice at 9 weeks of
age and that this phenotype is not altered by HDAC6
depletion (Fig. 6A). However, at the same age, levels of BDNF
protein in the cortex as measured by ELISA were comparable
between mice of all four genotypes (Fig. 6B). Equally, BDNF
protein levels in the striatum of Hdac6KO, R6/2 and Dble
mice were not different from those of WT mice (Fig. 6C).
Therefore, the decrease in Bdnf mRNA did not translate to a
reduction in BDNF protein. As Bdnf is expressed in the
striatum at a very low level (Fig. S4A) and it has been
published that most striatal BDNF protein originates in the
cortex [42], we conclude that there is no effect of HDAC6
ablation on the transport efficiency of BDNF from the cortex
to the striatum in either WT or R6/2 mice.
Discussion
Previous studies in cell culture models of HD have shown that
modulation of HDAC6 levels alters HD-related phenotypes
[25,28]. To extend this analysis to a mouse model, we investigated
the effects of HDAC6 genetic depletion in the R6/2 mouse. We
showed that Hdac6 knock-out mice (Hdac6KO) do not express
HDAC6 at the mRNA or protein levels and have hyperacetylated
tubulin in the cortex, striatum and cerebellum from 4 to 15 weeks
of age. We show that in the presence of the polyQ expanded R6/2
transprotein, levels of acetylated tubulin do not differ from that in
wild type animals and similarly, the HD mutation does not
interfere with the effect that HDAC6 ablation has on tubulin
hyperacetylation. We found that depletion of HDAC6 had no
effect on the aggregate load or BDNF levels in the R6/2 brain and
did not modify physiological or behavioural HD-related pheno-
types in R6/2 mice.
In this study, we have used mice in which the endogenous Hdac6
gene has been disrupted [36]. One possible concern with using
mice that do not express HDAC6 throughout development is that
Figure 4. No effect of Hdac6 knock-out on aggregate load or soluble transprotein levels. (A) Aggregate load was measured by Seprion
ligand ELISA (MW8 antibody) and (B) soluble transprotein levels were measured by TR-FRET (2B7-MW1 antibodies) in the cortex, hippocampus and
brain stem of R6/2 and Dble mice at 9 and 15 weeks. The average of the WT and Hdac6KO background signal was subtracted from both R6/2 and
Dble signals. The Dble signal is expressed as fold change of the R6/2 signal. * p,0.05; n$8/genotype. (C) Representative western blots with S830
anti-huntingtin antibody showing aggregated and soluble transprotein (Htt) in the cortex at 9 (upper panel) and 15 (lower panel) weeks. a-tubulin
(Tub) was used as a loading control. Specificity of S830 staining is confirmed by lack of signal in WT and Hdac6KO cortices. (D) Representative sagittal
sections from 9 week old mice showing the striatum immunostained with S830 antibody. Nuclei are counterstained with methyl green. Scale
bar=10 mm. Arrow=nuclear inclusion, arrowhead=cytoplasmic aggregate. Error bars represent SEM.
doi:10.1371/journal.pone.0020696.g004
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deficit. The HDAC6 mechanisms of action under investigation
here are based on HDAC6-tubulin interactions. Our demonstra-
tion that tubulin acetylation is increased in the brain from 4 to 15
weeks of age indicates that compensation has not occurred for the
HDAC6 target in which we are primarily interested and that the
constitutive Hdac6 knock-out mice used here are a suitable model.
There are numerous mouse models of HD, which include mice
transgenic for an N-terminal fragment of HTT, YAC and BAC
mice that are transgenic for full-length HTT gene and knock-in
mice in which an expanded CAG repeat has been introduced into
the mouse Hdh gene [43]. The HD cell culture model used by
Iwata and colleagues [25] to show that HDAC6 is required for
aggresome formation expressed an exon 1 huntingtin transprotein.
The R6/2 mice express an exon 1 N-terminal fragment of mutant
huntingtin [30] and therefore, they represent an appropriate
model with which to first follow-up on their findings. Also, recent
analysis has shown that the R6/2 mice develop HD-related
phenotypes that are highly comparable to a genetically accurate
knock-in mouse model of HD [31,33,34,35] and that, in these
knock-in mice, mutant huntingtin is processed to generate N-
terminal fragments [32]. Despite this, analysing the effects of the
Figure 5. Tubulin acetylation in the brains of Dble as compared to R6/2 mice. (A) Representative western blots showing acetylated tubulin
in Dble and R6/2 mice at 4, 9 and 15 weeks in cortex, striatum and cerebellum with a-tubulin as a loading control. (B) Densitometric quantification of
western blots presented in (A). Acetylated tubulin was normalised to a-tubulin and the relative signal for Dble mice expressed as fold change to R6/2.
Error bars represent SEM. * p,0.05, ** p,0.01, ***p,0.001; n$4/genotype.
doi:10.1371/journal.pone.0020696.g005
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genetically precise models might be considered important.
However, before embarking on such a project, it would be wise
to determine whether a reduction in HDAC6 levels has an effect in
cell culture models expressing a mutant version of full-length
huntingtin.
HDAC6 has been extensively characterised as being required
for the formation and subsequent autophagic degradation of the
aggresome [23,25,27]. In an HD cell culture model, HDAC6 was
required for aggresome formation and an increase in aggregate
load was observed upon HDAC6 knock-down [25]. Proteasome
inhibition resulted in an increase in ubiquitin positive aggregates in
Hdac6KO mouse embryonic fibroblasts as compared to wild type
cells indicating that HDAC6 is important for autophagy [44].
HDAC6 knock-down in a Drosophila melanogaster model of SBMA
exacerbated retinal degeneration and overexpression of HDAC6
decreased aggregate load and ameliorated retinal degeneration,
effects that required HDAC6 catalytic activity [26]. In keeping
with a role for HDAC6 in protein homeostasis, ubiquitin positive
aggregates have been reported to accumulate in the brains of
another strain of Hdac6KO mice by 6 months of age [27]. Given
that an increase in aggregation was not detected in R6/2 mice that
lack HDAC6, we conclude that either quality-control autophagy is
not important for the clearance of polyQ aggregates or that
HDAC6 is not essential for this process in the R6/2 mouse brain.
It is possible that the mechanism of aggregate handling could differ
between lower organisms/cell culture models and HD mice.
In cultured cells, an increase in tubulin acetylation has been
shown to enhance kinesin-1 binding and microtubule-based
transport [39]. BDNF is a kinesin-1 cargoe [28], which is actively
transported from the cortex to the striatum [42]. A recent study in
cells has shown that by increasing tubulin acetylation one can
increase BDNF cortico-striatal transport and that this is an HDAC6
dependent process [28]. In HD there is a well documented decrease
in cortical BDNF mRNA expression [41] and we have confirmed
that R6/2 mice at 9 weeks of age recapitulate this phenotype,
regardless of presence or absence of HDAC6. However, this did not
translate into a reduction in BDNF in either the cortex or the
striatum in accordance with some, but not all previously published
data [45,46,47], suggesting that R6/2 mice at 9 weeks do not
display a deficit in BDNF transport. If HDAC6 depletion increases
BDNF transport independent of the presence of the huntingtin
mutation, as has been reported [28], we would expect to see an
increase in striatal BDNF protein levels in both Hdac6KO and
double mutant mice. We did not observe any change in BDNF
levels. Strategies that increase BDNF levels have been shown to be
beneficial in R6/2 mice and other N-terminal fragment models
[45,48,49,50]. If small changes had occurred, that were beyond the
sensitivity of our detection method, they were not sufficient to
improve the phenotype of R6/2 mice.
There has been an increased focus on HDAC6 in neurodegen-
erative disease. In addition to the polyglutamine diseases, over-
expression of HDAC6 was protective in Drosophila melanogaster
models of Parkinson’s disease [51] and Alzheimer’s disease [52].
HDAC6 has also been found to localise to Lewy bodies in
Parkinson’s disease patient brains [23] and there is also evidence
supporting a role for HDAC6 in Alzheimer’s disease via its
association with tau [53]. Our finding that the knock-out of
HDAC6 does not affect the phenotype, aggregate load or BDNF
transport in R6/2 mice was very surprising. This study underlines
the importance of validating pathogenic mechanisms and
therapeutic targets in mammalian models. At the same time, our
findings indicate that the protective effect of broad range HDAC
inhibitors that has been observed in invertebrate and mouse HD
models [8] is not predominantly mediated via inhibition of
HDAC6. The current study is part of a wider project to investigate
the effects of the genetic depletion (knock-out or knock-down) of
specific HDACs on HD-related phenotypes in the R6/2 mouse.
Genetic reduction of Hdacs3, 5, 7 and 9 have not resulted in a
phenotypic improvement ([54] and unpublished data) whereas
knock-down of Hdac4 has shown beneficial effects (unpublished
data). Based on our data, we can conclude that HDAC6 inhibition
would not be a valid therapeutic strategy for HD.
Materials and Methods
Ethics statement
All experimental procedures performed on mice were approved
by the King’s College London Ethical Review Process Committee
and carried out under the UK Home Office License 70/6545.
Figure 6. Influence of Hdac6 knock-out on Bdnf mRNA and
protein levels. (A) Taqman qPCR assay showing a significant down-
regulation of Bdnf coding region mRNA expression in cortex of mice
carrying the R6/2 transgene. Data normalised to WT. ** p,0.01 (to
Hdac6KO), ***p,0.001 (to WT); n$4/genotype. (B–C) BDNF protein
content in the cortex (B) and striatum (C) measured by ELISA. Data
normalised to WT. n$3/genotype in (B) and n$4/genotype in (C). Error
bars represent SEM.
doi:10.1371/journal.pone.0020696.g006
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Hemizygous R6/2 mice were maintained by backcrossing R6/2
males to CBAxC57BL/6 F1 (CBF) females (B6CBAF1/OlaHsd,
Harlan Olac, UK) [30]. Hdac6 knock-out (Hdac6KO) mice [36] on
C57BL/6 background were backcrossed once to CBF. For the
R6/2xHdac6KO genetic cross, R6/2 males were bred to Hdac6
heterozygous females. At 4 weeks of age, mice were weaned into
cages of 5, each containing at least one representative of each
genotype. Animals were housed under 12 h light/12 h dark cycle,
with unlimited access to water and chow (Special Diet Services,
Witham, UK). Cages were environmentally enriched as described
[55]. Mice from the R6/2xHdac6KO cross were given mash food
consisting of powdered chow mixed with water during 4–6 and
12–15 weeks of age and sacrificed at 15 weeks.
Genotyping
Mice were genotyped by PCR of tail-tip DNA. R6/2 mice were
genotyped and their repeat sizes determined as described [34]. For
the Hdac6 genotyping, the primers were forward: 59-GTA-
CAATGTGGCTCACAGAA, reverse wt: 59-CAGGCACAG-
GAATATGAGTT and reverse KO: 59-CAACTCTGCCT-
CTCCTGG each used 1 mLa t1 0mM in one multiplex 10 mL
reaction, containing also 1 mL of 100 ng/mL DNA, 0.8 mL2 5m M
MgCl2,1 mL 2 mM dNTP, 1 mL Sigma 106PCR buffer and
0.1 mL Sigma Taq Polymerase (D4545, Sigma). Cycling condi-
tions were as follows: 94uC for 5 min, (94uC for 30 s, 64uC for 30 s
and 72uC for 1 min)640 followed by 10 min at 72uC.
Phenotypic assessment
The phenotypes of the mice from the R6/2xHdac6KO crosswere
assessed blind to genotype.Mice were weighed weeklyto the nearest
0.1 g. RotaRod performance was measured at 4 weeks of age for 4
consecutive days, 3 runs a day and after that at 8, 10, 12 and 14
weeks of age for 3 consecutive days, 3 runs a day, using an
accelerating (4–44 rpm in 5 min) Ugo Basile 7650 Rotarod, (Linton
Instrumentation, UK) modified as described [55]. Exploratory,
spontaneous motor activity was recorded at 5, 7, 9, 11 and 13 weeks
of age by placing mice in AM1053 activity cages for 30 min during
the day, as described previously [56]. Activity was the total number
of lower level beam breaks. Mobility was the number of at least two
consecutive beam breaks occurring in the lower level. Rearing was
the number of rearing beam breaks and centre rearing was the
number of rearing beam breaks occurring away from the cage walls.
Forelimb grip strength was assessed at 4 weeks of age and then
weekly from 11 to 14 weeks, always prior to RotaRod measure-
ments, with San Diego Instruments Grip Strength Meter (San
Diego, CA, USA) as described previously [55]. Mice were sacrificed
at 15 weeks of age and brains were weighed to the nearest 0.001 g.
Antibodies
The HDAC6 antibody was a kind gift from Dr. Tso-Pang Yao
[38]. Acetylated a-tubulin (6-11B-1, T7451) and a-tubulin (DM1A,
T9026) antibodies were purchased from Sigma. S830 is a sheep
polyclonal antibody raised against a GST tagged huntingtin exon 1
with53glutamines,characterized elsewhere[57] andwasgenerated
at Scottish Antibody Production Unit. MW8, MW1 [58] and 2B7
[59] were obtained from Novartis, Basel. Secondary peroxidase
coupled antibodies were purchased from Dako (anti-goat, anti-
mouse), Pierce (anti-rabbit) or KPL (anti-mouse for Seprion).
Sample preparation
For tubulin acetylation analysis, tissues were homogenised using
1% Triton X-100 buffer with 50 mM Tris-HCl pH 7.5, 150 mM
NaCl, 2 mM EDTA, 5 mM TSA (Trichostatin A, Sigma) and
10 mM nicotinamide (Sigma), supplemented with protease inhib-
itor cocktail (Roche). For HDAC6 immuno-detection, tissues were
homogenisedinRIPAbuffer(1%NP-40,0.5%Deoxycholate,0.1%
SDS, 50 mM Tris-HCl pH 8, 150 mM NaCl, 1 mM b-mercapto-
ethanol, 100 mM PMSF, 1 mM DTT) supplemented with protease
inhibitor cocktail (Roche). Samples were sonicated on ice for 10 s at
80 Hz (Vibracell Sonicator). Lysates were cleared by centrifugation
at 16 200 rcf for 15 min at 4uC. Protein concentration was
measured with Pierce BCA assay kit (Thermo Scientific). Samples
were diluted with 26 protein Laemmli buffer (1 M Tris-HCl
pH 6.8, 2.3% SDS, 4.5% glycerol, 10% b-mercaptoethanol,
0.001 g/mL bromophenol blue) and denatured for 5 min at 95uC.
Western blotting
Equal amounts of protein were loaded onto SDS polyacrylamide
gel with a size reference (Broad Range Protein Marker, Cell
Signalling or Spectra Broad Range Protein Ladder, Fermentas).
Proteins were transferred onto Protran nitrocellulose membrane
(Whatman) at 120 V for 90 min by submerged transfer apparatus
(Bio-Rad) in transfer buffer (20% v/v methanol, 25 mM Tris,
192 mM glycine).Membranes were blocked in 5% non-fat dried milk
in PBS for at least 1 hour. Primary antibodies were applied in 0.02%
PBS-Tween 20 (PBST) for 20 min (1:40000 acetylated a-tubulin;
1:30000 a-tubulin) or 1 hour (1:5000 S830) at room temperature or
overnight (1:250 HDAC6) at 4uC.Blots were washed thrice for 5 min
in 0.2% PBST and incubated with appropriate HRP coupled
secondary antibody(all 1:5000 except anti-rabbit1:20000).For signal
detection, GE Healthcare Enhanced Chemiluminescence detection
system and Amersham Hyperfilms (both GE Healthcare) were used
according to the manufacturer’s instructions. Signals were quantified
using a GS-800 densitometer (Bio-Rad).
Aggregate detection with Seprion ligand ELISA
For aggregate detection 2.5% lysates (w/v) were prepared by
homogenising tissue in RIPA. Aggregate capture and detection
were performed in Seprion ligand coated plates (Microsens) as
described [34].
TR-FRET
Time resolved - Fo ¨rster resonance energy transfer experiments
(TR-FRET) were performed as described [60].
BDNF ELISA
BDNF protein content was measured by the commercially
available ELISA kit (Promega) according to manufacturer’s
instructions modified as described [61]. Lysates were prepared at
2.2% dilution (w/v) and were not acid treated.
Taqman real time quantitative PCR
RNA extraction, cDNA synthesis, Taqman RT-qPCR and DCt
analysis were performed as described previously [62]. Housekeep-
ing genes (primer and probe mix purchased from Primer Design)
were chosen appropriate to the brain region analysed. For time-
course or across tissue analysis, several housekeeping genes were
tested and the most stable ones chosen. Primers for Hdac6
expression analysis were forward: 59 - GGAGACAACCCAGTA-
CATGAATGAA; reverse: 59 - CGGAGGACAGAGCCTGTAG
and the probe was 59-FAM-TATCTGCATCCGAACTCATA-
TTCCTGTGCCTG-TAMRA. Primers for Bdnf coding region
were forward: 59 - GGGTCACAGCGGCAGATAAA; reverse: 59
- GCCTTTGGATACCGGGACTT; and the probe was: 59 -
FAM - TCTGGCGGGACGGTCACAGTCC - TAMRA.
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Whole brains were snap frozen in isopentane at 250uC.
Immunohistochemistry was performed as described [31].
Statistical Analysis
Data from the R6/2xHdac6KO cross were analysed with SPSS
using one way ANOVA or General Linear Model ANOVA with
Greenhouse-Geisser correction for non-sphericity. Data from
qPCR and tubulin acetylation assay were analysed with Microsoft
Excel using Student’s t-test (two tailed).
Supporting Information
Figure S1 Hdac6 knock-out has no effect on spontane-
ous motor activity in WT or R6/2 mice. Five minute moving
averages for Activity, Mobility, Rearing and Centre rearing at 5, 7,
9, 11 and 13 weeks of age for WT, Hdac6KO, R6/2 and Dble mice.
n$16/genotype (as shown in Fig. 3A).
(TIF)
Figure S2 Hdac6 knock-out does not change aggregate load
in the brain or muscle. (A) Aggregate load was measured by
Seprion ligand ELISA with the MW8 antibody in the cortex,
hippocampus and brain stem of R6/2 and Dble mice at 4 weeks.
n$5/genotype. (B) Representative western blot with S830 anti-
huntingtin antibody showing aggregated and soluble transprotein (Htt)
in the cortex at 4 weeks. a-tubulin (Tub) was used as a loading control.
Specificity of S830 staining is confirmed by lack of signal in WT and
Hdac6KO cortices. (C) Densitometric quantification of soluble Htt
f r o mw e s t e r nb l o t ss h o w ni n( A )a n dF i g .4 C .H t ts i g n a lw a sn o r m a l i s e d
to a-tubulin and the relative signal for Dble mice expressed as fold
change to R6/2 for each time point. (D) Soluble (2B7-MW1
antibodies, upper panel) and aggregated (MW8-MW8 antibodies,
lower panel) transprotein levels were measured by TR-FRET in the
cortex at 9 and 15 weeks. Data normalised to R6/2 at 9 weeks.
*p ,0.05; n$8/genotype. (E) Aggregate load was measured by
Seprion ligand ELISA with the MW8 antibody and soluble
transprotein levels were measured by TR-FRET (2B7-MW1 antibod-
ies) in the quadriceps muscle at 9 and 15 weeks. Data normalised to
R6/2 at each time point. n$7/genotype. Error bars represent SEM.
(TIF)
Figure S3 The increase in tubulin acetylation in brain is
comparable between Hdac6KO and Dble mice. (A)
Representative western blots showing acetylated tubulin (Ac-tub)
in Dble and Hdac6KO mice at 4, 9 and 15 weeks in cortex,
striatum and cerebellum with a-tubulin (Tub) as a loading control.
There was insufficient tissue to perform the analysis on striatum at
9 and 15 weeks. (B) Densitometric quantification of western blots
presented in (A). Acetylated tubulin was normalised to a-tubulin
and the relative signal for Dble mice expressed as fold change to
Hdac6KO. Error bars represent SEM. KO - Hdac6KO, Dble -
Hdac6KOxR6/2; n$3/genotype.
(TIF)
Figure S4 Similar levels of BDNF protein in striatum,
cortex and hippocampus despite very low Bdnf mRNA
striatal expression. (A) Bdnf mRNA coding region expression in
WT mice at 9 weeks between cortex, striatum and hippocampus.
Data normalised to Ubc and expressed as fold change of cortex.
n$3/genotype. ** p,0.01 (to cortex) *** p,0.001 (to cortex and to
hippocampus) (B) BDNF protein content measured by ELISA in
cortex, striatum, hippocampus and liver in WT mice at 9 weeks of
age. Data normalised to cortex. * p,0.05; n=3/genotype. Error
bars represent SEM.
(TIF)
Table S1 Statistical analysis of the influence of time (30 min
duration) and genotype(s) on the spontaneous motor activity
parameters: activity, mobility, rearing and centre rearing present-
ed as p - values calculated via ANOVA General Linear Model with
Greenhouse-Geisser correction.
(DOC)
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